Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2013-06-17 Major Shareholding Noti…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2013
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding percentage for a specific holder (FMR LLC) in the issuer (Swedish Orphan Biovitrum AB (publ)). It shows the 'Before the transaction' and 'After the transaction' share counts and voting rights percentages, and explicitly states the 'Reason for major shareholding notification Sell'. This content directly corresponds to the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The structure and content are typical of regulatory filings reporting changes in significant ownership thresholds.
2013-06-17 English
Sobi får FDA-godkännande att tillverka läkemedelssubstansen för Kineret® med partnern Boehringer Ingelheim
Regulatory Filings Classification · 95% confidence The document is a press release dated June 11, 2013, announcing that Sobi received approval from the FDA for manufacturing the active substance for Kineret® at a partner's facility. This type of announcement, detailing a specific regulatory event (FDA approval for manufacturing/distribution) that is not a full financial report (like 10-K or IR) or a general shareholder vote result, fits best under a general regulatory announcement or a specific event announcement. Since it is a specific corporate event announcement regarding regulatory clearance and partnership logistics, and not a standard financial report, it is classified as a Regulatory Filing (RNS) as a broad category for non-standard, material corporate news, or potentially a Capital/Financing Update (CAP) if the focus was on the commercial impact, but RNS is more appropriate for general regulatory news releases that don't fit other specific categories like ER, DIV, or DIRS. Given the options, RNS serves as the best fit for a material, non-financial regulatory update press release.
2013-06-11 Swedish
Sobi gets FDA approval to manufacture substance for Kineret® with partner Boehringer Ingelheim
Regulatory Filings Classification · 91% confidence The document is a press release dated June 11, 2013, announcing that Sobi received FDA approval for manufacturing substance for Kineret® via a Supplemental Biologics License Application (sBLA). This is a specific corporate announcement regarding regulatory clearance and supply chain management, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a general earnings release (ER). It is a specific operational update that doesn't fit the primary financial report categories. Since it is a specific announcement regarding a regulatory/operational milestone, and not a general regulatory filing fallback (RNS), it is best classified as a general announcement related to the business operations, which often falls under Regulatory Filings (RNS) if no other specific category applies. However, given the context of FDA approval and supply chain establishment, it is a significant corporate event announcement. Since there is no specific category for 'Regulatory Approval Announcement' or 'Operational Update', RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, as it is a formal announcement to the market about a regulatory event.
2013-06-11 English
Sobi utnämner Mats-Olof Wallin till Finansdirektör
Board/Management Information Classification · 98% confidence The document is a short press release dated May 17, 2013, announcing the permanent appointment of Mats-Olof Wallin as the Chief Financial Officer (CFO) of Swedish Orphan Biovitrum AB (Sobi). This announcement concerns a change in senior management/board composition. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit, as it covers 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report, earnings release, or transcript.
2013-05-17 Swedish
Sobi appoints Mats-Olof Wallin as permanent Chief Financial Officer
Board/Management Information Classification · 99% confidence The document is a press release announcing a specific change in senior personnel: the appointment of Mats-Olof Wallin as the permanent Chief Financial Officer (CFO). This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2013-05-17 English
Kommuniké från Sobis årsstämma
AGM Information Classification · 98% confidence The document is explicitly titled "Kommuniké från Sobis årsstämma" (Communiqué from Sobi's Annual General Meeting) and details the resolutions passed by the shareholders regarding financial statements, board members, remuneration guidelines, and incentive programs. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document is a summary/communiqué, not a full presentation or voting result declaration, making AGM-R the best fit over AGM-R (which is for presentations) or DVA (which is for official voting results). Given the direct title, confidence is high.
2013-04-26 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.